|
|
| | AS2553627 Basic information |
| Product Name: | AS2553627 | | Synonyms: | AS2553627;1-Piperidinepropanenitrile, 3-(dipyrrolo[2,3-b:2',3'-d]pyridin-1(6H)-yl)-4-methyl-β-oxo-, (3R,4R)- | | CAS: | 1251906-10-1 | | MF: | C18H19N5O | | MW: | 321.38 | | EINECS: | | | Product Categories: | | | Mol File: | 1251906-10-1.mol |  |
| | AS2553627 Chemical Properties |
| Boiling point | 666.3±55.0 °C(Predicted) | | density | 1.38±0.1 g/cm3(Predicted) | | pka | 6.12±0.60(Predicted) |
| | AS2553627 Usage And Synthesis |
| Description | AS2553627 is a novel JAK inhibitor. AS2553627 prevents chronic rejection in rat cardiac allografts. AS2553627 potently inhibited JAK kinases but showed no inhibition of other kinases, including TCR-associated molecules. In a rat cardiac transplant model, oral administration of AS2553627 alone or co-administration with a sub-therapeutic dose of tacrolimus effectively prolonged cardiac allograft survival, suggesting the efficacy in treating acute rejection. AS2553627 may be a therapeutic candidate for the prevention of not only acute but also chronic rejection in cardiac transplantation. | | Uses | AS2553627 is a type of JAK inhibitor, with IC50 values of 0.46, 0.30, 0.14, and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively. AS2553627 can inhibit the proliferation of human and rat T cells stimulated by IL-2, with IC50 values of 2.4 and 4.3 nM, respectively. AS2553627 can reduce cardiac allograft vasculopathy and fibrosis in a rat heart transplant model, effectively extending survival rates. AS2553627 can be used to prevent acute and chronic rejection in heart transplants[1]. | | IC 50 | JAK1; JAK2; JAK3; Tyk2 | | References | [1] Nakamura K, et al. AS2553627, a novel JAK inhibitor, prevents chronic rejection in rat cardiac allografts. Eur J Pharmacol. 2017 Feb 5;796:69-75. DOI:10.1016/j.ejphar.2016.12.025 |
| | AS2553627 Preparation Products And Raw materials |
|